TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

KONVOMEP

OMEPRAZOLE
Gastroenterology Approved 2022-08-30
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-08-30
Routes
ORAL
Dosage Forms
FOR SUSPENSION

Companies

Active Ingredient: OMEPRAZOLE , SODIUM BICARBONATE

KONVOMEP Approval History

Loading approval history...

What KONVOMEP Treats

2 indications

KONVOMEP is approved for 2 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Gastric Ulcer
  • Gastrointestinal Bleeding
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KONVOMEP FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

KONVOMEP is indicated in adults for: short-term treatment (4 to 8 weeks) of active benign gastric ulcer. reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients. KONVOMEP is a combination of omeprazole, a proton pump inhibitor (PPI) and sodium bicarbonate, indicated in adults for: •Treatment of active benign gastric ulcer •Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients

KONVOMEP Patents & Exclusivity

Latest Patent: Feb 2040

Patents (9 active)

US11771686 Expires Mar 1, 2040
US11911473 Expires Jul 16, 2039
US12440566 Expires Jul 16, 2039
US12329752 Expires Jul 16, 2039
US10751333 Expires Jul 16, 2039
US11103492 Expires Jul 16, 2039
US11633478 Expires Jul 16, 2039
US12042539 Expires Jul 16, 2039
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.